These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15745044)

  • 21. Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice.
    Alvarez-Lajonchere L; González M; Alvarez-Obregón JC; Guerra I; Viña A; Acosta-Rivero N; Musacchio A; Morales J; Dueñas-Carrera S
    Biotechnol Appl Biochem; 2006 Apr; 44(Pt 1):9-17. PubMed ID: 16367740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine.
    Nuzzaci M; Vitti A; Condelli V; Lanorte MT; Tortorella C; Boscia D; Piazzolla P; Piazzolla G
    J Virol Methods; 2010 May; 165(2):211-5. PubMed ID: 20132840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses against HCV-NS3 after accidental infection with HCV-NS3 recombinant vaccinia virus.
    Eisenbach C; Neumann-Haefelin C; Freyse A; Korsukéwitz T; Hoyler B; Stremmel W; Thimme R; Encke J
    J Viral Hepat; 2007 Nov; 14(11):817-9. PubMed ID: 17927619
    [No Abstract]   [Full Text] [Related]  

  • 24. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
    Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
    J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological properties of purified recombinant HCV particles with an epitope-tagged envelope.
    Takahashi H; Akazawa D; Kato T; Date T; Shirakura M; Nakamura N; Mochizuki H; Tanaka-Kaneko K; Sata T; Tanaka Y; Mizokami M; Suzuki T; Wakita T
    Biochem Biophys Res Commun; 2010 May; 395(4):565-71. PubMed ID: 20399750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.
    Lauer GM
    J Infect Dis; 2013 Mar; 207 Suppl 1():S7-S12. PubMed ID: 23390305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response.
    Thammanichanond D; Moneer S; Yotnda P; Aitken C; Earnest-Silveira L; Jackson D; Hellard M; McCluskey J; Torresi J; Bharadwaj M
    Clin Immunol; 2008 Sep; 128(3):329-39. PubMed ID: 18524682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.
    Schlaphoff V; Klade CS; Jilma B; Jelovcan SB; Cornberg M; Tauber E; Manns MP; Wedemeyer H;
    Vaccine; 2007 Sep; 25(37-38):6793-806. PubMed ID: 17686555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse.
    Eisenbach C; Freyse A; Lupu CM; Weigand K; Ernst E; Hoyler B; Stremmel W; Bugert JJ; Encke J
    Vaccine; 2006 Jun; 24(24):5140-8. PubMed ID: 16713033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.
    Alvarez-Lajonchere L; Dueñas-Carrera S
    Int Rev Immunol; 2012 Jun; 31(3):223-42. PubMed ID: 22587022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.
    Feinstone SM; Hu DJ; Major ME
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S25-32. PubMed ID: 22715210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA vaccination against hepatitis C.
    Dueñas-Carrera S
    Curr Opin Mol Ther; 2004 Apr; 6(2):146-50. PubMed ID: 15195926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus and the immune system: a concise review.
    Gremion C; Cerny A
    Rev Med Virol; 2005; 15(4):235-68. PubMed ID: 15782389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
    Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
    J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Induction of cytotoxic T cell responses in mice by immunization with multi-CTL epitope-based anti-HCV DNA vaccine].
    Shi L; Liu S; Sheng L; Meng ZJ; Yuan YK
    Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):385-6. PubMed ID: 16732921
    [No Abstract]   [Full Text] [Related]  

  • 36. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.
    Jin B; Wang RY; Qiu Q; Sugauchi F; Grandinetti T; Alter HJ; Shih JW
    Immunology; 2007 Sep; 122(1):15-27. PubMed ID: 17451465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C vaccine: supply and demand.
    Strickland GT; El-Kamary SS; Klenerman P; Nicosia A
    Lancet Infect Dis; 2008 Jun; 8(6):379-86. PubMed ID: 18501853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus (HCV): a review of immunological aspects.
    Irshad M; Khushboo I; Singh S; Singh S
    Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immune evasion mechanisms of hepatitis C virus. Review].
    Porto-Espinoza L; Cuadra-Sánchez C; Moronta R; Monsalve-Castillo F; Callejas-Valero D
    Invest Clin; 2006 Mar; 47(1):71-82. PubMed ID: 16562646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.
    Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sallberg M
    J Infect Dis; 2005 Dec; 192(12):2112-6. PubMed ID: 16288375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.